Fleury (FLRY3.SA) Stock Price
Fleury Price
Over the last 19 years Fleury grew revenue by 16.1% annually, reaching 8.29 B BRL. Earnings per share have grown at 12.5% per year over the last 19 years. For Fleury, the net margin of 7.4% is down versus 9.0% a few years ago. At today's price the dividend yield works out to roughly 7.71%. The payout ratio is around 149% of earnings. The dividend has grown at 20.5% per year over the past 15 years. The consensus 12-month price target for Fleury is 18.36 BRL, about 15.5% below where the stock trades today. Of 19 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 53% above its 52-week low.
Fleury stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Fleury over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fleury stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fleury's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Fleury Price |
|---|---|
| 9/25/2026 | 21.74 BRL |
| 9/24/2026 | 22.00 BRL |
| 9/23/2026 | 21.99 BRL |
| 9/22/2026 | 21.90 BRL |
| 9/21/2026 | 21.96 BRL |
| 9/18/2026 | 21.38 BRL |
| 9/17/2026 | 21.45 BRL |
| 9/16/2026 | 21.37 BRL |
| 9/15/2026 | 21.27 BRL |
| 9/14/2026 | 21.34 BRL |
| 9/11/2026 | 21.23 BRL |
| 9/10/2026 | 20.95 BRL |
| 9/9/2026 | 20.35 BRL |
| 9/8/2026 | 20.75 BRL |
| 9/4/2026 | 20.39 BRL |
| 9/3/2026 | 20.10 BRL |
| 9/2/2026 | 19.67 BRL |
| 9/1/2026 | 19.21 BRL |
| 8/31/2026 | 19.43 BRL |
| 8/28/2026 | 18.66 BRL |
| 8/27/2026 | 18.79 BRL |
| 8/26/2026 | 18.66 BRL |
| 8/25/2026 | 18.64 BRL |
| 8/24/2026 | 18.64 BRL |
| 8/21/2026 | 18.68 BRL |
| 8/20/2026 | 18.13 BRL |
| 8/19/2026 | 18.42 BRL |
| 8/18/2026 | 18.05 BRL |
| 8/17/2026 | 18.14 BRL |
| 8/14/2026 | 18.23 BRL |
Fleury Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Fleury Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB BRL |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB BRL |
| EBITB BRL |
| EBIT MARGIN% |
| NET INCOMEB BRL |
| NET INCOME GROWTH% |
| DIVIDENDDIV.BRL |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.89 | 2.10 | 2.38 | 2.66 | 2.91 | 2.97 | 3.87 | 4.46 | 6.47 | 7.68 | 8.29 | 9.21 | 9.85 | 10.41 | 11.18 | 9.96 |
| 12.87 | 10.67 | 13.69 | 11.79 | 9.05 | 2.27 | 30.33 | 15.26 | 44.97 | 18.76 | 7.90 | 11.04 | 7.02 | 5.63 | 7.47 | -10.96 |
| 26.50 | 28.67 | 30.89 | 30.33 | 30.57 | 27.23 | 29.08 | 27.11 | 24.54 | 27.89 | 23.98 | 23.98 | 23.98 | 23.98 | 23.98 | 23.98 |
| 0.50 | 0.60 | 0.74 | 0.81 | 0.89 | 0.81 | 1.13 | 1.21 | 1.59 | 2.14 | 1.99 | 2.21 | 2.36 | 2.50 | 2.68 | 2.39 |
| 0.24 | 0.34 | 0.48 | 0.50 | 0.58 | 0.49 | 0.67 | 0.73 | 0.92 | 1.32 | 1.22 | 1.57 | 1.69 | 1.84 | 1.94 | 1.95 |
| 12.41 | 16.13 | 19.97 | 18.88 | 20.03 | 16.43 | 17.23 | 16.45 | 14.14 | 17.23 | 14.76 | 17.00 | 17.17 | 17.71 | 17.33 | 19.53 |
| 0.11 | 0.23 | 0.32 | 0.33 | 0.31 | 0.26 | 0.35 | 0.31 | 0.42 | 0.62 | 0.61 | 0.76 | 0.86 | 0.98 | 1.05 | 1.05 |
| 25.88 | 113.08 | 40.35 | 3.44 | -5.74 | -17.95 | 36.33 | -12.03 | 37.79 | 45.63 | -0.65 | 24.02 | 13.44 | 13.70 | 6.84 | 0.48 |
| – | – | – | – | – | – | – | – | – | – | – | 0.80 | 0.83 | 0.86 | – | – |
| – | – | – | – | – | – | – | – | – | – | – | – | 3.75 | 3.61 | – | – |
| 319.21 | 337.88 | 355.56 | 341.17 | 340.14 | 337.37 | 442.32 | 356.28 | 484.02 | 544.27 | 545.05 | 545.05 | 545.05 | 545.05 | 545.05 | 545.05 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Fleury generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fleury retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fleury's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Fleury has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fleury's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Fleury stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Fleury Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Fleury business model & stock analysis
Fleury SWOT Analysis
Strengths
Fleury SA has established itself as a leading healthcare provider in Brazil, boasting a strong brand reputation and a wide range of medical services.
The company has a vast network of hospitals, labs, and clinics, allowing it to serve a large customer base and generate significant revenue.
Fleury SA's technological capabilities and investment in advanced medical equipment enable them to offer high-quality and accurate diagnostic services.
Weaknesses
One weakness of Fleury SA is its heavy dependency on the Brazilian healthcare system. Any changes in government policies or regulations can significantly impact the company's operations and profitability.
The high cost of healthcare services provided by Fleury SA may limit access for some potential customers.
Fleury SA's expansion plans outside of Brazil are limited, potentially hindering its growth opportunities in international markets.
Opportunities
With the increasing demand for healthcare services in Brazil, Fleury SA has the opportunity to expand its market share and reach a larger customer base.
There is a growing trend towards preventive healthcare, which opens up opportunities for Fleury SA to develop and offer new services focused on early detection and disease prevention.
International expansion into emerging markets could diversify Fleury SA's revenue streams and reduce its reliance on the Brazilian market.
Threats
Intense competition within the Brazilian healthcare industry poses a threat to Fleury SA's market position and profitability.
Economic downturns and fluctuations in healthcare spending can negatively impact Fleury SA's revenue and financial performance.
Changes in healthcare regulations and reimbursement policies can create challenges for Fleury SA in terms of cost control and compliance.
Fleury Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Fleury historical P/E ratio, EBIT multiple, and P/S ratio
Fleury annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Fleury's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Fleury's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Fleury's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Fleury shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Fleury stock splits
Since 2017, a total of 2.1 shares have been converted from one Fleury share.
Fleury Dividend History
17 years of dividend payments · 2 consecutive increases
Fleury dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Fleury dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Fleury forecasts and price targets in September 2026
Analyst Price Targets 2026Fleury Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/5/2026 | 0.43BRL | - | 2.42 BBRL | - | 2026 Q3 |
| 8/6/2026 | 0.34BRL | 0.40BRL | 2.25 BBRL | - | 2026 Q2 |
| 5/7/2026 | 0.35BRL | 0.37BRL | 2.20 BBRL | - | 2026 Q1 |
| 3/5/2026 | 0.13BRL | 0.18BRL | 2.04 BBRL | - | 2025 Q4 |
| 11/5/2025 | 0.13BRL | 0.34BRL | 2.03 BBRL | - | 2025 Q3 |
| 8/6/2025 | 0.30BRL | 0.28BRL | 2.04 BBRL | - | 2025 Q2 |
| 2/26/2025 | 0.16BRL | 0.15BRL | 1.83 BBRL | - | 2024 Q4 |
| 11/7/2024 | 0.36BRL | 0.35BRL | 1.94 BBRL | - | 2024 Q3 |
| 8/8/2024 | 0.32BRL | 0.29BRL | 1.97 BBRL | - | 2024 Q2 |
| 5/9/2024 | 0.30BRL | 0.31BRL | 1.93 BBRL | - | 2024 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Fleury stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Fleury shareholder structure
| % | Name |
|---|---|
41.35614% | |
1.95414% | |
1.52210% | |
1.07216% | |
1.00047% | |
0.91752% |
Fleury Beneficial Ownership Filings (SEC 13D/G)
Fleury Executives and Management Board
15 members · avg. age 59 · 20 % women
Management
Ms. Jeane Tsutsui (55)
Chief Executive Officer, Member of the Executive Board · since 2021
Mr. Jose de Almeida Filippo (64)
Chief Financial and Investor Relations Officer, Member of the Executive Board
Ms. Patricia Bertoncello (42)
Member of the Executive Board, Service Units Officer
Mr. Roberto Meirelles (55)
Member of the Executive Board, L2L and Operations Support Officer
Mr. Edgar Rizzatti (49)
Member of the Executive Board, Medical, Technical and Process Officer · since 2021
Board of Directors
Mr. Marcio Mendes (51)
Chairman of the Board
Mr. Fernando Alberto (56)
Vice Chairman of the Board
Mr. Luiz Cappi (73)
Director
Mr. Rui de Barros Maciel (79)
Director
Mr. Samuel dos Santos (79)
Director · since 2017
Mr. Ivan Gontijo
Director
Frequently asked questions about Fleury
The business model of Fleury SA, a leading medical diagnostics company in Brazil, revolves around providing high-quality healthcare services through its network of diagnostic imaging, clinical analysis, and other medical services. Fleury SA aims to ensure accurate diagnoses, offer timely access to medical procedures, and deliver exceptional customer experience. By investing in advanced technology, top-notch professionals, and continuous innovation, Fleury SA effectively meets the healthcare needs of patients across the country. With its strong reputation and diverse range of diagnostic services, Fleury SA strives to maintain its position as a market leader in Brazil's healthcare industry.
Fleury SA is primarily active in the healthcare industry.
The main competitors of Fleury SA in the market include Grupo Fleury, DASA, and Hermes Pardini.
Fleury SA is a leading healthcare company based in Brazil. With a rich history dating back to 1926, Fleury has continually evolved and expanded its operations to become one of the most reputable diagnostic medicine providers in the country. Over the years, the company has developed a strong reputation for its advanced diagnostic techniques and high-quality services, encompassing radiology, pathology, and clinical analysis. With a strong focus on technological innovation, Fleury has consistently invested in cutting-edge equipment and research, enabling them to deliver accurate and reliable results to patients. Today, Fleury SA stands as a trusted name in the healthcare industry, providing comprehensive diagnostic solutions to improve patient outcomes.
Fleury SA, a renowned company, has achieved remarkable milestones throughout its history. Having established a strong presence in the healthcare sector, Fleury SA continuously strives for excellence. Some significant achievements include expanding its network and becoming one of the largest healthcare providers in Brazil. Additionally, Fleury SA has consistently prioritized innovation, implementing advanced technology and processes to deliver high-quality diagnostics and medical solutions. The company's commitment to patient-centric care and a strong focus on research & development have further solidified its position as a trusted leader in the industry. Fleury SA's relentless pursuit of growth and unwavering dedication to improving healthcare services have contributed to its notable achievements.
Fleury SA is primarily present in Brazil, where it operates a wide network of diagnostic medicine and healthcare facilities. With its headquarters in São Paulo, the company is a leader in medical laboratory services, operating in several states across the country. Fleury SA's commitment to providing high-quality diagnostic services has allowed it to expand its presence to other regions of Brazil, catering to a diverse range of patients and medical professionals.
Fleury SA represents a strong set of values and corporate philosophy. With a focus on excellence and innovation, the company strives to deliver the highest quality healthcare services to patients. Fleury SA is committed to providing accurate diagnoses, personalized care, and cutting-edge medical technology. Through continuous improvement, the company aims to surpass industry standards and meet the evolving needs of its customers. With a reputation for professionalism and integrity, Fleury SA upholds a patient-centric approach, putting the well-being and satisfaction of individuals at the forefront. By encompassing these values, Fleury SA remains a trusted leader in the healthcare industry.
Analysts currently set an average price target of 17.77 BRL for the Fleury stock (median: 18.36 BRL), implying -18.3 % versus the latest price. The consensus is based on 19 analyst ratings.
18 analysts currently rate the Fleury stock: 11 recommend buying, 5 holding and 2 selling. For 2026, analysts expect Fleury to generate revenue of 9.21 B BRL and earnings per share of 1.39 BRL.
Converted at the current exchange rate, the Fleury share trades at 3.67 EUR (21.74 BRL).
The Fleury share (FLRY3.SA) is listed on 2 stock exchanges, including: B3 (São Paulo) (FLRY3.SA).
Fleury SA is a company specializing in medical diagnostics and health services. Founded in 1926, the company is headquartered in Sao Paulo, Brazil. With over 9,000 employees and a revenue of more than 2.2 billion Brazilian Reals, Fleury SA is one of the largest medical service companies in South America. The business model of Fleury SA is based on three core areas: diagnostics, health services, and research and development. In diagnostics, the company enables disease identification and offers comprehensive diagnostic solutions. The portfolio of diagnostic services is very broad and includes imaging and radiological diagnostics, laboratory and pathology services, genetic testing, and screening for pregnancy-related diseases. In the field of health services, Fleury SA offers a wide range of services for individuals and companies looking to improve prevention, wellness, and quality of life. The services range from health counseling and health programs to outpatient surgery and rehabilitation facilities. In research and development, the company is interested in driving innovation in the fields of medical diagnostics and health services. Fleury SA invests heavily in the development of new technologies and solutions to improve the accuracy and efficiency of its diagnostic services, as well as in collaboration with academic institutions and other companies. The company is known for adhering to very high quality standards in all aspects of its services. Fleury SA is ISO 9001 certified and is committed to continuously working towards customer satisfaction and process optimization. The company is proud to offer state-of-the-art technology and top-notch medical professionals to provide customers with the best possible service. In addition to its business areas, Fleury SA also offers a variety of products, such as diagnostic instruments and consumables for medical professionals, medical software, and health products for the general public. The products are designed to meet the needs of medical professionals and private consumers and meet the highest quality standards. Overall, Fleury SA has an impressive track record in the field of medical diagnostics and health services. The company has established itself as a trusted provider of high-quality and innovative solutions over the past decades and is committed to continuing to lead the industry with excellence and groundbreaking innovations.
The expected revenue of Fleury is 9.21 B BRL. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Fleury is 759.49 M BRL. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Fleury is currently 15.60. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fleury stock.
The price-to-sales ratio (P/S) of Fleury is currently 1.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fleury stock.
The Eulerpool Quality Score for Fleury is 8/10.
The ISIN of Fleury is BRFLRYACNOR5. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Fleury is FLRY3.SA. The ticker symbol is used to trade Fleury shares on the stock exchange.
Over the past 12 months, Fleury paid a dividend of 1.68 BRL . This corresponds to a dividend yield of about 7.71 %. For the coming 12 months, Fleury is expected to pay a dividend of 0.83 BRL.
The current dividend yield of Fleury is 7.71 %.
Fleury pays a dividend, distributed in the months of March, August, December.
Fleury paid dividends every year for the past 16 years.
For the upcoming 12 months, dividends amounting to 0.83 BRL are expected. This corresponds to a dividend yield of 3.81 %.
Fleury is assigned to the 'Health' sector.
In the year 2025, Fleury distributed 1.68 BRL as dividends.
The dividends of Fleury are distributed in BRL.
Fleury stock
Fleury Peer Group
Fleury Ticker
Fleury FIGI
All fundamentals and in-depth analysis of Fleury
Our stock analysis for Fleury stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fleury. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.